Guidant Likely Will Bow Out Of AAA Race As Stakes Rise Too High
This article was originally published in The Gray Sheet
Executive Summary
Guidant is poised to exit the abdominal aortic aneurysm market, which could eventually reach $1 bil., citing declining sales and a lack of adoption by vascular surgeons of its Ancure AAA endovascular stent graft